International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, PR China.
Hepatology. 2013 Aug;58(2):680-91. doi: 10.1002/hep.26391. Epub 2013 Jul 1.
Macrophages (Mψ) are the major component of infiltrating leukocytes in tumors and exhibit distinct phenotypes according to the microenvironment. We have recently found that signal regulatory protein α (SIRPα), the inhibitory molecule expressed on myeloid cells, plays a critical role in controlling innate immune activation. Here, we identify that SIRPα is down-regulated on monocytes/Mψ isolated from peritumoral areas of hepatocellular carcinoma (HCC) samples, while its level is moderately recovered in intratumor Mψ. In vitro assays demonstrate that SIRPα expression is significantly reduced on Mψ when cocultured with hepatoma cells. This reduction is partly due to the soluble factors in the tumor microenvironment. Knockdown (KD) of SIRPα prolongs activation of nuclear factor kappa B (NF-κB) and PI3K-Akt pathways as Mψ encounter tumor cells, leading to an increased capacity of Mψ for migration, survival, and proinflammatory cytokine production. Enhanced Stat3 and impaired Stat1 phosphorylation are also observed in tumor-exposed SIRPα-KD Mψ. Adoptive transfer with SIRPα-KD Mψ accelerates mouse hepatoma cells growth in vivo by remolding the inflammatory microenvironment and promoting angiogenesis. SIRPα accomplishes this partly through its sequestration of the signal transducer Src homology 2-containing phosphotyrosine phosphatase (SHP2) from IκB kinase β (IKKβ) and PI3K regulatory subunit p85 (PI3Kp85).
These findings suggest that SIRPα functions as an important modulator of tumor-polarized Mψ in hepatoma, and the reduction of SIRPα is a novel strategy used by tumor cells to benefit their behavior. Therefore, SIRPα could be utilized as a potential target for HCC therapy.
巨噬细胞(Mψ)是肿瘤浸润白细胞的主要成分,根据微环境表现出不同的表型。我们最近发现,表达于髓样细胞上的抑制性分子信号调节蛋白α(SIRPα)在控制固有免疫激活中发挥关键作用。在这里,我们发现 SIRPα在肝癌(HCC)样本肿瘤周围区域分离的单核细胞/巨噬细胞(Mψ)中下调,而其水平在肿瘤内 Mψ 中适度恢复。体外实验表明,当与肝癌细胞共培养时,Mψ 上的 SIRPα表达显著降低。这种减少部分是由于肿瘤微环境中的可溶性因子。当 Mψ 遇到肿瘤细胞时,SIRPα 的敲低(KD)延长核因子 kappa B(NF-κB)和 PI3K-Akt 途径的激活,导致 Mψ 迁移、存活和促炎细胞因子产生的能力增加。在肿瘤暴露的 SIRPα-KD Mψ 中也观察到 Stat3 增强和 Stat1 磷酸化受损。用 SIRPα-KD Mψ 进行过继转移可通过重塑炎症微环境和促进血管生成来加速小鼠肝癌细胞在体内的生长。SIRPα 通过将信号转导 Src 同源 2 结构域包含的磷酸酪氨酸磷酸酶(SHP2)从 IκB 激酶β(IKKβ)和 PI3K 调节亚基 p85(PI3Kp85)隔离来实现这一点。
这些发现表明 SIRPα 作为肝癌中肿瘤极化 Mψ 的重要调节剂发挥作用,SIRPα 的减少是肿瘤细胞用来获益其行为的一种新策略。因此,SIRPα 可作为 HCC 治疗的潜在靶点。